menu
    • menu
    [{"orgOrder":0,"company":"Aqemia","sponsor":"Cathay Innovation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Aqemia","amount2":0.040000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Aqemia \/ Cathay Innovation","highestDevelopmentStatusID":"4","companyTruncated":"Aqemia \/ Cathay Innovation"},{"orgOrder":0,"company":"Aqemia","sponsor":"Servier","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Aqemia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aqemia \/ Servier","highestDevelopmentStatusID":"4","companyTruncated":"Aqemia \/ Servier"},{"orgOrder":0,"company":"Aqemia","sponsor":"Wendel Growth","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Aqemia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aqemia \/ Wendel Growth","highestDevelopmentStatusID":"4","companyTruncated":"Aqemia \/ Wendel Growth"},{"orgOrder":0,"company":"Aqemia","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"FRANCE","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Aqemia","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aqemia \/ Sanofi","highestDevelopmentStatusID":"2","companyTruncated":"Aqemia \/ Sanofi"},{"orgOrder":0,"company":"Aqemia","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2025","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Aqemia","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Aqemia \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Aqemia \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Aqemia

    Menu

    Aqemia

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Aqemia

    France arrow
    Peptide Therapy Summit
    Not Confirmed

    Aqemia

    France arrow
    Peptide Therapy Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Undisclosed

    Therapeutic Area : Oncology

    Study Phase : Discovery Platform

    Sponsor : Undisclosed

    Deal Size : $7.4 million

    Deal Type : Funding

    DEALS_DEV arrow-down

    Aqemia Expands Into Small-Molecule RNA Targeting with $7.4M Grant

    Details : Through the funding Aqemia aims to develop novel small-molecule drugs against this emerging and promising class of therapeutic targets.

    Product Name : Undisclosed

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    April 01, 2025

    Lead Product(s) : Undisclosed

    Therapeutic Area : Oncology

    Highest Development Status : Discovery Platform

    Sponsor : Undisclosed

    Deal Size : $7.4 million

    Deal Type : Funding

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Aqemia

    France arrow
    Peptide Therapy Summit
    Not Confirmed

    Aqemia

    France arrow
    Peptide Therapy Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Undisclosed

    Therapeutic Area : Oncology

    Study Phase : Discovery Platform

    Sponsor : Cathay Innovation

    Deal Size : $38.0 million

    Deal Type : Funding

    DEALS_DEV arrow-down

    AQEMIA Hits $100M Funding Milestone, Eyes Trials and Global Expansion in UK

    Details : Aqemia will use the proceeds to continue to advance its technology platform to transform drug discovery, designing innovative and safe small-molecule for cancers.

    Product Name : Undisclosed

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    December 10, 2024

    Lead Product(s) : Undisclosed

    Therapeutic Area : Oncology

    Highest Development Status : Discovery Platform

    Sponsor : Cathay Innovation

    Deal Size : $38.0 million

    Deal Type : Funding

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Aqemia

    France arrow
    Peptide Therapy Summit
    Not Confirmed

    Aqemia

    France arrow
    Peptide Therapy Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Undisclosed

    Therapeutic Area : Oncology

    Study Phase : Preclinical

    Sponsor : Wendel Growth

    Deal Size : $64.5 million

    Deal Type : Series A Financing

    DEALS_DEV arrow-down

    AQEMIA Boosts Series A Funding to €60M to Advance Therapeutic Pipeline

    Details : AQEMIA will use proceeds to enhance its small molecule drug discovery pipeline and scale its GenAI and deep physics drug discovery platform.

    Product Name : Undisclosed

    Product Type : Undisclosed

    Upfront Cash : Undisclosed

    January 30, 2024

    Lead Product(s) : Undisclosed

    Therapeutic Area : Oncology

    Highest Development Status : Preclinical

    Sponsor : Wendel Growth

    Deal Size : $64.5 million

    Deal Type : Series A Financing

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    Aqemia

    France arrow
    Peptide Therapy Summit
    Not Confirmed

    Aqemia

    France arrow
    Peptide Therapy Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Undisclosed

    Therapeutic Area : Oncology

    Study Phase : Discovery

    Sponsor : Servier

    Deal Size : Undisclosed

    Deal Type : Expanded Collaboration

    DEALS_DEV arrow-down

    Servier and Aqemia Extend Collaboration on Undruggable Target in Immuno-Oncology

    Details : Aqemia has employed its unique quantum-physics-inspired artificial intelligence technology to identify innovative, patentable molecules that are experimentally active on an undruggable target in immuno-oncology.

    Product Name : Undisclosed

    Product Type : Undisclosed

    Upfront Cash : Undisclosed

    September 01, 2023

    Lead Product(s) : Undisclosed

    Therapeutic Area : Oncology

    Highest Development Status : Discovery

    Sponsor : Servier

    Deal Size : Undisclosed

    Deal Type : Expanded Collaboration

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    05

    Aqemia

    France arrow
    Peptide Therapy Summit
    Not Confirmed

    Aqemia

    France arrow
    Peptide Therapy Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Undisclosed

    Therapeutic Area : Technology

    Study Phase : Discovery

    Sponsor : Sanofi

    Deal Size : $140.0 million

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    AQEMIA Announces a Major Multi-year Collaboration of $140 Million with Sanofi

    Details : Under the collaboration, AQEMIA will design novel drug molecules using its generative AI and deep physics algorithms and platform and Sanofi will leverage its global research and development expertise to accelerate the development of therapeutic drugs.

    Product Name : Undisclosed

    Product Type : Undisclosed

    Upfront Cash : Undisclosed

    May 12, 2023

    Lead Product(s) : Undisclosed

    Therapeutic Area : Technology

    Highest Development Status : Discovery

    Sponsor : Sanofi

    Deal Size : $140.0 million

    Deal Type : Collaboration

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth